<DOC>
	<DOCNO>NCT00748579</DOCNO>
	<brief_summary>The purpose study ( CY 1124 ) evaluate effect CK-1827452 , cardiac myosin activator , myocardial systolic performance , myocardial oxygen consumption , myocardial efficiency patient heart failure confirm unique preclinical pharmacological profile CK- 1827452 substantially patient heart failure .</brief_summary>
	<brief_title>Phase II Study Effect CK-1827452 Injection Myocardial Efficiency</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Clinical indication leave right heart catheterization Willing able provide inform consent Male female 18 year age great Symptomatic heart failure ( ≥ NYHA Class II ) Ejection fraction ≤ 35 % Patient sinus rhythm Patient consider suitable health opinion investigator , determine : A prestudy physical examination clinical abnormality opinion investigator would preclude participation study physical symptom sign consistent stable heart failure For female patient : Postmenopausal sterilize , childbearing potential , breastfeeding , pregnancy test negative , intention become pregnant 90 day follow study , use contraceptive drug device Acute myocarditis Hypertrophic , restrictive , constrictive cardiomyopathy Congenital heart disease Known leave ventricular thrombus Significant stenotic valvular disease ( severe aortic stenosis , mitral stenosis ) Poorly control hypertension ( SBP &gt; 180 mmHg ) Pacemaker dependent ventricular rhythm Detectable troponin CKMB &gt; ULN timepoint within 14 day enrollment Acute coronary syndrome revascularization procedure within 30 day enrollment ≥ 50 % stenosis leave main coronary artery Plan immediate revascularization procedure ( PCI CABG ) GFR ≤ 35 ml/min/1.73 m2 Modification Diet Renal Disease ( MDRD ) Equation need renal replacement therapy Known hepatic impairment ( total bilirubin &gt; 3 mg/dL , ALT AST &gt; 2 time upper limit normal ) Has receive investigational drug device within 30 day enrollment Has prior treatment CK1827452</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>